Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 1864578, 19 pages
https://doi.org/10.1155/2017/1864578
Research Article

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib

1Division of Science, School of Science Engineering and Technology, Abertay University, Dundee DD1 1HG, UK
2Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XU, UK
3Division of Computing and Mathematics, School of Design and Informatics, Abertay University, Dundee DD1 1HG, UK

Correspondence should be addressed to Yusuf Y. Deeni; ku.ca.yatreba@ineed.y

Received 6 May 2017; Revised 9 September 2017; Accepted 16 October 2017; Published 19 December 2017

Academic Editor: Javier Egea

Copyright © 2017 Ibrahim H. Kankia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Ibrahim H. Kankia, Hilal S. Khalil, Simon P. Langdon, Peter R. Moult, James L. Bown, and Yusuf Y. Deeni, “NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 1864578, 19 pages, 2017. doi:10.1155/2017/1864578